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Determining what is driving idiopathic parkinsonism
(IP) necessitates stepping-back to consider the whole
clinical entity. The prevailing paradigm is that a hit-
and-run insult leads to cold degeneration of
dopaminergic neurons. The broad epidemiological brush
reveals an interesting cluster of associations: familial
aggregation, rural living, farm exposure, source of drink-
ing water (wells and rivers), and the apparent protective
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Abstract
Background: We examine the effect of eradicating Helicobacter in idiopathic
parkinsonism (IP). Marked deterioration, where eradication-therapy failed,
prompted an interim report in the ﬁrst 20 probands to reach de-blinding.
The null-hypothesis, ‘‘eradication has no effect on principal outcome, mean
stride length at free-walking speed,’’ was rejected. We report on study
completion in all 30 who had commenced post-treatment assessments.
Methods: This is a randomized, placebo-controlled, parallel-group efﬁcacy
study of eradicating biopsy-proven (culture and⁄or organism on histopathol-
ogy) Helicobacter pylori infection on the time course of facets of IP, in pro-
bands taking no, or stable long-t½, anti-parkinsonian medication. Persistent
infection at de-blinding (scheduled 1-year post-treatment) led to open active
eradication-treatment.
Results: Stride length improved (73 (95% CI 14–131) mm⁄year, p = .01) in
favor of ‘‘successful’’ blinded active over placebo, irrespective of anti-parkin-
sonian medication, and despite worsening upper limb ﬂexor rigidity (237
(57–416) Nm · 10
)3⁄year, p = .01). This differential effect was echoed
following open active, post-placebo. Gait did not deteriorate in year 2 and 3
post-eradication. Anti-nuclear antibody was present in all four proven (two
by molecular microbiology only) eradication failures. In the remainder, it
marked poorer response during the year after eradication therapy, possibly
indicating residual ‘‘low-density’’ infection.
We illustrate the importance of eradicating low-density infection, detected
only by molecular microbiology, in a proband not receiving anti-parkinso-
nian medication. Stride length improved (424 (379–468) mm for 15 months
post-eradication, p = .001), correction of deﬁcit continuing to 3.4 years.
Flexor rigidity increased before hydrogen-breath-test positivity for small
intestinal bacterial overgrowth (208 (28–388) Nm · 10
)3, p = .02), increased
further during (171 (67–274), p = .001) (15–31 months), and decreased
(136 (6–267), p = .04) after restoration of negativity (32–41 months).
Conclusion: Helicobacter isan arbiter of progression, independent ofinfection-load.
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spousal approach to environmental causality. Marked,
multifarious, relevant differences (physiological⁄psycho-
motor⁄dermatological), between spouses of IP probands
and control couples were difﬁcult to explain by selective
mating or learned⁄reactive behavior (for review, see
[2]). That is the spouses appear a short, but highly signi-
ﬁcant, distance down the pathway. This and relative
lymphopenia [3], in a large group of IP probands and
spouses, suggested adult transmission of a primer. More-
over, half of the probands and a third of their spouses
had chronic bowel abnormality [2]. There is both
systemic and nigro-striatal immune activation in IP.
Indeed, we found biological gradients between measures
of IP and circulating markers of inﬂammation. The
concept of a systemic infection primer emerged.
Back in 1965, Strang [4] observed an excess of previ-
ously diagnosed peptic ulcer in IP. However, the link had
remained unexplored after recognition of Helicobacter
pylori-associated gastritis in 1983 [5]. Most Helicobacter
infections are transmitted where there is close contact, as
between parent or sibling and infant. This accords with
our ﬁnding that IP probands and their siblings share
facets of the syndrome and increased prevalence of
anti-urease antibody seropositivity [2]. Finding
biological gradients between measures of IP, and their
progression over 4 years, and a discriminant index for IP
based on the serum immunoblot H. pylori antibody
proﬁle strengthens the case for causality. Increased
frequency of clinically deﬁnite IP in urea-breath-test
(UBT) positive spouses of probands [3] suggests that, in
these circumstances, transmission of a primer can turn
containment [6] into progression. Helicobacter emerged as
a potential arbiter for progression.
In the natural history, brady⁄hypokinesia-predomi-
nant parkinsonism progresses to rigidity predominant
[7]. Balance worsens, with increase in body sway, more
reliance on visual correction and narrowing of ambula-
tory, coronal foot separation. If Helicobacter infection
was the master switch in the pathogenic circuitry, its
eradication should halt progression. Some recovery
would be expected had it been a source of autoimmu-
nity [1] or speciﬁc toxins [8], and microglial neuro-
trophic⁄homeostatic support was restored [9]. However,
disease modiﬁcation rather than global attenuation
could result should a subsidiary pathogenic pathway be
opened up.
We report on completion of the ﬁrst study of the efﬁ-
cacy of H. pylori eradication on time-trends in the facets
of IP, in probands receiving no, or only long elimina-
tion half-time (t½), anti-parkinsonian medication. An
interim report [10] was made when the statistician was
alerted to marked deterioration where eradication
therapy failed. Persistence of Helicobacter, even at ‘‘low-
density’’ (detected only by molecular microbiology on
gastric biopsies) appeared detrimental. Similar outcomes
of eradicating ‘‘low-density’’ and UBT-positive infection
would further an autoimmune hypothesis. The history
of a proband, whose biopsies were culture⁄histology
negative but positive on polymerase chain reaction
(PCR) assays, illustrates the case.
Understanding what is being measured, what inﬂu-
ences it and exploring effect modiﬁcation are keys to
our approach [2]. All detected eradication failures [10]
were anti-nuclear antibody (ANA) seropositive, as,
indeed, are a quarter of probands [3]. ANA status is,
thus, examined as an outcome-modiﬁer in apparent
successes. Similarly, the reduced blood lymphocyte
count of IP [3] might be associated with impaired clear-
ance of residual organisms.
Methods
Deﬁnition of Subjects
We have adopted Calne’s broad deﬁnition of ‘‘clinically
deﬁnite’’ IP [11], rather than applying guidelines for
the prediction of a single brain-pathology. The syn-
drome itself is the target, not the pathology. Realisti-
cally, different ‘‘neurodegenerative’’ pathologies occur
in the same individual [12]. Between individuals, path-
ological response to the same environmental exposure
may differ according to genetic predisposition and other
modifying factors.
The study was approved by local ethics committees,
written consent obtained from all participants. Figure 1
shows the study proﬁle. Responders to a call for volun-
teers were screened for Helicobacter (by UBT and serol-
ogy) and immune status [10]. Accompanying spouses⁄
partners were offered screening. Inclusion criteria were
independently living probands with biopsy-proven
H. pylori infection (on histology or culture). At endos-
copy, ‘‘light’’ sedation (intravenous midazolam, maxi-
mum dose 4 mg) was an option.
Subjects receiving no anti-parkinsonian medication
were preferred. Any ‘‘background’’ anti-parkinsonian
medicine had to be long acting (making use of levodopa
an exclusion), at steady state, and evenly spaced with
reference to t½ to avoid iatrogenic ﬂuctuations in
performance. It must remain constant throughout.
Other exclusion criteria were: (1) secondary parkin-
sonism, ‘‘parkinsonism-plus’’ syndromes or other wider
clinical entities [11,13]; (2) clinical depression (Beck’s
Hopelessness score [14]), dementia (cognitive ability
scales: Modiﬁed Tooting Bec score £8⁄16 and⁄or
Mini-mental Score <24⁄30 [15,16]) or other mental
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cardiovascular⁄respiratory symptoms during normal
activities; (5) other progressive or resolving disorders
affecting physical ability or performance, or sufﬁcient
underlying incapacity to prevent assessments; (6) UK
MRC muscle strength score <4⁄5; (7) concurrent therapy
with potentially anti-dopaminergic drugs, or with hypn-
otics or sedatives; (8) recent change in life situation; (9)
serious pathology, such as ulcer or neoplasm (any esoph-
ageal, gastric or duodenal lesion biopsied in line with
standard practice) or inﬂammatory bowel disease.
Protocol
This is a randomized, double-blind, placebo-controlled,
parallel-group study of the effect of eradicating H. pylori
on facets of parkinsonism. A computer generated
randomization was applied to consented probands,
numbered according to order of entry. De-blinding was
scheduled for 54 weeks, or sooner if (1) current
life-style threatened by disease progression (temporal
end-point), (2) other exit criteria met (development of
other medical conditions needing specialist attention;
falls with serious injury⁄fracture; initiation of⁄modiﬁca-
tion to anti-parkinsonian medication), or (3) requested
by subject. Judgments on premature de-blinding were
made by two physicians, blind to randomization.
Helicobacter status was not re-investigated until after
de-blinding. Probands who remained UBT positive after
placebo were offered the corresponding active regimen.
Those who received active had a UBT and were offered
endoscopic biopsy. Follow-up was scheduled for 5 years
post-eradication, but curtailed if any background medi-
cation was changed, new maintenance therapy started,
or if another life-changing illness diagnosed.
Acquisition of objective measures of facets of parkin-
sonism and independent video analysis (blind to
sequence⁄treatment) were used to minimize bias.
Trial Medication
One group received 1 week’s triple therapy, the other
matched-placebo capsules⁄tablets. Placebos were sup-
plied by manufacturer, the only difference being the
absence of active moiety. Medication was pre-packed
according to patient number. The usual treatment was
20 mg omeprazole, 500 mg clarithromycin, and 1 g
amoxicillin, 12-hourly. Twelve-hourly metronidazole
400 mg and⁄or 6-hourly tetracycline 500 mg were to
be used where there was in vitro insensitivity and⁄or
suspected intolerance. The appropriate three trial-
medication containers were dispensed.
Where there was evidence that a blind- or open-
active regimen failed, a different regimen was offered,
taking into account any new anti-microbial sensitivi-
ties⁄inferences from PCR. Compliance was checked
over the telephone.
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183 healthy subjects with definite IP (including 8 
couples) and 116 other spouses/partners 
responded to call. Screen for Helicobacter &
immune status offered* 
Remainder 
advised‡ on 
Helicobacter &
immune status 
31 IP subjects eligible & 
consented to participate† 
(only 1 partner of a couple 
permitted) 
Prescribed active according to 
initial antimicrobial sensitivities††
4 with evidence of failure of therapy  
(2 of whom initially allocated to active) 
Follow-up: 5 years post-eradication or to start/change 
of background medication or to other life-changing illness  
Further eradication therapy
††
Entered into double-blind 
eradication study§  
30 de-blinded at 1 year post-
trial medication or on 
reaching temporal endpoint 
(1 drop-out immediately after 
randomized treatment¶) 
16 had received placebo: all 
remained UBT-positive** 
14 had received active 
Figure 1 Study proﬁle in probands with idiopathic parkinsonism (IP)
and their spouses⁄partners. *For full analysis of screen, see [10].
†29⁄31 positive on all three screening tests: all were seropositive on
immunoblot proﬁle, one was urea-breath-test (UBT) negative, another
had an equivocal anti-urease enzyme-linked immunosorbent assay
(ELISA) value. Twenty-nine were culture positive for Helicobacter pylori
(including the one UBT negative), remaining two (both UBT positive)
were positive on PCR assay. H. pylori-like organisms on histology in
30, exception being culture positive. ‡With reference to further
investigation and treatment. §Diarrhea during trial-medication (active)
in one: compliance not affected and de-blinding as per schedule
at 54 weeks. ¶No medical reason. **Any apparent spontaneous
eradication was to be conﬁrmed by endoscopic biopsy. ††Following
open active, UBT offered at 6 weeks, with, if negative, a delay to
endoscopy of at least 4 months.
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Two baseline assessments, at a set time of day, preceded
randomization. After the allocated treatment, assess-
ments were scheduled 6-weekly. Follow-up after open
active was as for blinded active. Where there was no
evidence of continuing infection after an active treat-
ment, follow-up was reduced, at 54 weeks, to 12-weekly
for 1 year, and then to 24-weekly.
Clinical Measurements
Cardinal outcome criteria were:
1 Brady⁄hypokinesia of gait. The primary outcome was
hypokinesia, measured by mean stride length at free-
walking speed, during ‘‘steady-state’’ [17], over 18 m in
a 1.85 m wide corridor. Stride length usefully deﬁnes
treatment effects and, when corrected for relevant
demographic⁄anthropometric characteristics, discrimi-
nates well between those with and without diagnosed
parkinsonism [18,19]. Rested subjects walked unaided,
‘‘at your own speed’’ [18]. A second walk followed
5 minutes rest. Stride length and speed were analyzed.
2 Rigidity of upper limb. To measure rigidity [20], the
supported forearm was moved horizontally, at a
controlled velocity, through a 40  arc about the elbow.
The side judged more rigid at the initial assessment was
studied. Swing duration was 1.3 seconds, the pause
between varying (1–3 seconds) to reduce the effect of
anticipation. One minute’s acclimatization preceded 2½
minute recording. A computer interface unit measured
the torque required for passive displacement against
position (sampling interval 25 ms). Mean torque for each
swing was calculated, and the grand means taken for
extension and for ﬂexion. Greater rigidity in ﬂexor
muscles than in extensor is characteristic of parkinsonism.
3 Tremor of hands. Video recordings were used to assess
tremor, as attaching devices to the hand can modify it. A
ﬁxed camera ﬁlmed a plan-view of hands, resting semi-
prone on the table in front of the seated subject. It
recorded any tremor over 1 minute before and during
stress from repeating back, in reverse order, series of spo-
ken random numbers [20]. The video archive was rated
by an independent assessor, blind to date and treatment,
using a visual-analog scale (from 0, the most intrusive
tremor witnessed between-subject, to 100, no tremor),
for each recording condition. Two others reviewed a
sample (seven videos of one subject, whose unprovoked
tremor ranged between extremes): their ratings did not
differ signiﬁcantly from the main assessor’s (mean differ-
ence 6 (95% CI )13, 25) and 3 ()7, 12), paired t tests).
4 Postural abnormality. Functional and anatomical abnor-
mality contribute to imbalance in IP [7]. Total angular
displacement (sway) in the sagittal plane was measured
[7]: subjects stood at ease, with eyes open for 1 minute,
then closed for three. Anatomical posture was gauged by
height (with buttocks and heels against a wall, but
otherwise standing relaxed) and, during walking, by
mean coronal foot separation at mid-swing [7,18].
Complementary criteria were:
Stance⁄walk videos. A ‘‘blinded’’ independent assessor
analyzed the entire archive of anterior and lateral
videos of standing (15 seconds) followed by walking
(over 12.5 and 6.5 m, respectively). Lateral perspective
was from the side on which rigidity measured. Another
assessor reviewed a sample (total 153 anterior and 128
lateral videos, from 20 subjects). On a global rating
visual-analog scale (0 mm representing a subject’s worst
walk, 100 his⁄her best), there was no signiﬁcant differ-
ence in their ratings (mean difference )1.8 ()6.5, 2.9)
for anterior, 1.0 ()4.5, 6.5) lateral).
Scales were constructed to describe brady⁄hypokine-
sia and tremor (from 0, most severe abnormality
witnessed between-subject, to 100, normality). The
brady⁄hypokinesia scale took equal account of 12
items, each formulated from correlated observations
(e.g. arm swing on more-rigid and less-rigid sides
during walk). Each observation contributed equally to
an item. The tremor scale (more-rigid side only) took
equal account of three observations (during walk from
anterior and lateral perspectives, and at stance from
lateral). Chronbach’s alpha [21] provides an estimate of
within-scale consistency. It was 0.84 and 0.91 for
12-item brady⁄hypohypokinesia and 3-observation
tremor scale, respectively, indicating satisfactory scales.
Psychometric disability. Reaction time was measured as
that taken to lift left or right index-ﬁnger from its
touch-sensitive support [22]. Two seconds before the
imperative, an alerting signal did, or did not, warn
whether left or right was to be lifted. ‘‘Cognitive inefﬁ-
ciency’’ was measured by the ratio, warned⁄unwarned.
Other measurements. Rested supine, standing (immediate
and at 1 and 3 minutes) and post-exercise blood pres-
sure and pulse were measured, as was body weight
(unshod, without outer clothing).
Histologic, Microbiologic and Immunologic
Methods
Infection was proven by: (1) gastritis associated with He-
licobacter-like organisms on microscopy (any of six biop-
sies: anterior and posterior antral, incisurial, anterior
and posterior corporal, cardiac), and⁄or (2) culture of H.
pylori (either of two biopsies: antral and corporal, couri-
ered to the Helicobacter Reference Laboratory), or, if
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Biopsies, ordered on a cellulose acetate strip, were ﬁxed
(10% buffered-formalin) and processed to parafﬁn
blocks. Hematoxylin and eosin stained sections were
examined and classiﬁed (Updated Sydney System [23]),
organisms sought using cresyl-fast violet. The Helicobacter
Reference Laboratory operating procedures for H. pylori
culture were used, with in vitro testing for susceptibility,
to clarithromycin, amoxicillin, metronidazole and tetra-
cycline, by Etest (AB Biodisk, Solna, Sweden) [24]. Cul-
ture negative biopsies were tested using a PCR targeting
16S rRNA (primer pair HP1⁄HP2 [25]) and vacA
(Vac3624F⁄Vac3853R [26]) genes: sensitivities on gastric
biopsies were 90 and 85%, respectively, speciﬁcities 99
and 98% [26]. Where positive, clarithromycin suscepti-
bility was determined using real-time PCR [26].
In the screen, Helicobacter status was deﬁned by [
13C]
urea-breath-test (INFAI, Kestrel Healthcare Ltd., Basing-
stoke, UK) and serology. Serum was stored at )20  C. An
enzyme-linked immunosorbent assay (ELISA) for anti-
urease-IgG antibody (SIA417A; Delta Biologicals, Rome,
Italy) had between-assay coefﬁcients of variation, for the
samples assayed in singlicate, of 5.8 and 8.1% at an
ELISA value of 1.7 and 3.2. An ELISA value >2.2 is the
recommended cut-point of seropositivity, from equivo-
cal⁄seronegative (1.8 to 2.2⁄<1.8). Presence⁄absence of
deﬁned antibody bands on Western blotting was scored
according to the manufacturer’s system (RIDA Helico-
bacter Blot IgG; Quadratech Diagnostics Ltd., Epsom,
UK). Blots and the developed control (k) strip, supplied
with each kit, were scanned and magniﬁed, to maximize
precision of band detection. A score >12 is the recom-
mended cut-point of positivity, from equivocal⁄negative
(11 to 12⁄<11). Each assay kit contains a negative and a
positive quality control: all read true.
Serum was screened for ANA by indirect immunoﬂu-
orescence using Hep2010 cells and rat stomach, kidney
and liver composite tissue block (Biochip slides;
Euroimmun UK, Pontypool, UK). Secondary antibodies
were FITC-conjugated polyclonal rabbit anti-human IgG
(Dako, Ely, UK). Lymphocyte subset counts were
obtained by ﬂow cytometry: four-color ﬂuorescent cell
labeling using the MultiTEST kit in TruCOUNT tubes
and a FACSCalibur ﬂow cytometer (Becton Dickinson,
San Jose, CA, USA). These standard immunological
procedures were subject to the UK national external
quality assurance scheme.
Statistical Methods
Sample size calculation was based on the primary out-
come criterion, stride length. It was estimated that, for
a signiﬁcance level of .05 and a power of .8, 56 subjects
(28 in each group) would be required to show a differ-
ence between active and placebo treatments of (SD)
at 1 year, where SD is the between-subject standard
deviation.
When the statistician was alerted to an obvious
difference in clinical progression where blinded active
eradication therapy failed [10], 30 subjects had com-
menced the post-treatment assessments, 20 had reached
de-blinding. In this 20, an intention-to-treat analysis on
the ﬁnal measurement of stride length in the blinded-
phase showed a statistically signiﬁcant difference in favor
of active treatment (p = .02). The null-hypothesis was
rejected: ‘‘a p-value of .05 from a small sample can be
quite strong evidence, but one of .05 from a larger
sample is always weak’’ [27]. Steering and ethical
committees were informed, recruitment halted. All 30
entered were to continue to and beyond de-blinding.
Detailing drop-outs and outcome of treatment failure
are integral to any efﬁcacy study. In the double-blind
protocol analysis, nature of treatment refers to ‘‘success-
ful’’ active (no evidence of failure) or to placebo. Linear
mixed models [28] were used to analyze repeated
measures of primary, other cardinal and complementary
outcome criteria. Fixed effects in the model were:
nature of treatment; time since treatment; any back-
ground anti-parkinsonian medication; their interactions
(between: treatment and time, background-medication
status and time, treatment and background-medication
status); mean baseline measurement; and, where
relevant, demographic ⁄anthropometric characteristics.
A random effect for subject was included in the model:
thus, it contained both a subject-level random intercept
and the usual residual term, each assumed to have a
normal distribution. Fixed effects were kept in the
model regardless of whether they reached conventional
levels of statistical signiﬁcance. Models were ﬁtted via
the xt commands within stata 10 [29]. After visual
inspection for broad similarity and linearity of individual
subjects’ temporal trends, the efﬁcacy of eradication was
assessed via the interaction between nature of, and time
since, treatment. Estimated annual change in an out-
come was obtained directly, or by linear combination of
model coefﬁcients, according to nature of treatment.
Variables exhibiting a positively skewed distribution
were transformed (natural logarithmic) to approximate
normality.
Case History of Eradication Therapy for Low-
Density H. pylori in Idiopathic Parkinsonism
This patient with untreated IP (5 years from diagnosis)
provided the ﬁrst opportunity to examine prospectively
the effect of eradicating low-density H. pylori infection.
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eligible for the efﬁcacy study, where all recruited had
frank Helicobacter infection (UBT and⁄or culture
positive). Her spouse was UBT positive, and her mother
had recently been treated for Helicobacter. Her sister and
late father ‘‘always had stomach problems,’’ the latter
having been treated for peptic ulcer. There was no family
history of diagnosed parkinsonism, but her mother had a
tremor. She had a 2-year history of acid regurgitation
and ‘‘needing food between meals,’’ and felt bloated and
nauseated on rising and after eating. She complained of
nocturnal hot-sweats. She has never smoked. Table 1
gives further baseline characteristics, including gastric
biopsy results. The likelihood of a biopsy giving a false
positive with multiple PCR primer pairs is small [34].
Following two baseline clinical assessments, she
received a 1-week anti-Helicobacter course (12-hourly
ranitidine bismuth citrate 400 mg, amoxicillin 1 g, and
clarithromycin 500 mg). Her spouse was treated
contemporaneously. Her assessments were repeated
approximately 2-monthly over the next 3.4 years.
Biopsies taken 15 months post-treatment showed no
evidence of Helicobacter (same protocol⁄team): the serum
immunoblot score had become negative by 2.5 years.
Hydrogen-breath-tests for small intestinal bacterial over-
growth (SIBO) were carried out, using a 25 g lactulose
test dose, following 24-hour deprivation of dairy prod-
ucts (and any medicinal lactulose) and a breakfast of
250 mL black tea⁄coffee or water. Hydrogen concentra-
tions were measured (Micro Medical Ltd., Rochester,
UK) pre-dose and at 15-minute intervals for 4 hours
after. Criterion for positivity was two consecutive values
[35] ‡cut-point of meter manufacturer. A generalized
estimating equation model, with ﬁrst order autore-
gressive correlation structure, was used to estimate the
average performance in four time-periods, relating to
Helicobacter status and hydrogen-breath-test status.
Results
Intention-to-Treat Analysis
Table 2 gives baseline clinical measurements and pre-
treatment histopathology⁄microbiology, according to
randomization: there was no clinically important imbal-
ance in measurements between the two groups.
Table 1 Baseline characteristics of patient with low-density Helicobacter pylori
Characteristic On presentation
Personal Female, aged 59 years, weight 84 kg, height 1.6 m, body mass index 32.8 kg⁄m
2
Manifestations Brady⁄hypokinesia-predominant idiopathic parkinsonism, untreated
Blood proﬁle Full bood count, B-lymphocyte and T subset counts: normal. Serum vitamin B12, folate and ferritin: normal.
Homocysteine = 21 lmol⁄L (target <16). Autoantibody screen: anti-intrinsic factor positive, otherwise nega-
tive including anti-nuclear antibody
Helicobacter screen Urea-breath-test negative: immunoblot score positive: anti-urease ELISA not done
Gastric biopsy sites Three sets (antral and corporal): two sets for histology, one microbiology
Histology Mild chronic antral⁄corporal inﬂammation, no polymorphonuclear activity or Helicobacter-like organisms
seen. No atrophy or intestinal metaplasia
Culture Negative
Molecular microbiology
a Positive for Helicobacter DNA from three different vacA regions (s1, m2, and intermediate) in antrum, for
mid-region (m2) only in corpus; both biopsies cagA negative
aGenomic DNA extracted from biopsies (Qiagen DNeasy Tissue kit, Qiagen Ltd, Crawley, UK) and the presence of H. pylori genomic DNA tested by
PCR ampliﬁcation.
Primers speciﬁc for three regions of vacA gene used: (1) signal-region (primers VA1-F and VA1-R [30]); (2) mid-region (primers VAG-F and VAG-R
[31]); (3) intermediate-region between signal and mid (primers DL2 and VacR9 (see [32] for primer sequence)).
Signal- and mid-region primers determine vacA type by product size and hence are expected to give a product for all H. pylori strains. The
additional primer pair DL2⁄VacR9 amplify the entire intermediate-region, and are not speciﬁc for i-region type, hence are also expected to give a
product for all H. pylori strains. PCR product sizes were estimated by agarose gel electrophoresis with reference to positive control strains and a
commercial DNA ladder. Product for signal-region reaction matched size of that for s1 control strain 60190 (259 bp); mid-region product matched
that obtained for m2-type control strain Tx30a (645 bp). Intermediate-region ampliﬁcation gave a band similar to that of 60190 (361 bp), the
expected size for primer used. Negative control samples (no template) demonstrated that contamination of reagents with H. pylori DNA (a likely
reason for a false-positive result) had not occurred.
The s1 signal-region allele associated with in vitro vacuolating activity, s2 Vac protein being nonvacuolating. Mid-region affects epithelial cell
binding, m1 toxin vacuolating a wider variety of cells [32]. Thus, s1⁄m1 strains are vacuolating, s2⁄m2 nonvacuolating and s1⁄m2 variable.
Intermediate-region interacts in vacuolation, according to subtype (not determined). Decreased propensity toward gastric disease expected with
cagA negativity.
Primers for cagA were cag2 and cag4 [33].
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ment of the primary outcome, stride length, in the
blinded-phase (n = 14 for active, n = 16 placebo) gave
a p-value of .005 (adjusted for baseline stride length
(p < .001), age, height, and gender [19] not contribut-
ing to variance explained). Rejection of the null-
hypothesis was conﬁrmed, a multiplicity adjustment
not considered necessary. The magnitude of effect was
equivalent to 1.02 times the between-subject standard
deviation: the study had been designed to detect
0.75(SD) with a sample size of 56. The corresponding
time-trend in stride length was 69 mm⁄year better after
blinded active than after placebo (active 59 (95% CI
26, 92); placebo )10 ()46, 25)).
Given concern about safety, an intention-to-treat
analysis was also performed on the ﬁnal measurement
in torque to extend the forearm. It gave a p-value of
.006 (adjusted for baseline (p = .001), there being no
pre-identiﬁed personal covariate [20]). The magnitude
of effect was only 0.11 (SD). The corresponding time-
trend in torque was 205 Nm · 10
)3⁄year worse after
blinded active than after placebo (247 (136, 359);
42 ()55, 139), respectively). Torque to ﬂex was
unaffected.
Protocol Analysis
Table 3 gives the double-blind protocol analysis of
time-trends in clinical measurements (two proven erad-
ication failures of blinded active excluded). Numbers
reaching a temporal end-point and duration of follow-
up are given. Table 3 also compares outcomes in the
subsequent year, between probands initially allocated
to active and those receiving open active after placebo
(two failures of open active excluded).
Stride length improved (by, on average, 73 mm⁄year)
following successful blinded active compared with
placebo. Free-walking speed was unaffected by the
double-blind treatment, but optimizing stride length
would have made gait more energy-efﬁcient.
Excluding those receiving background anti-parkinso-
nian medication did not diminish the size of treatment-
effect on stride length (Fig. 2). That is the effect of
eradicating Helicobacter was not attributable to improved
absorption of, or response to, anti-parkinsonian
medication.
The statistically signiﬁcant effect on stride length of
successful open active in year 2 is illustrated in Fig. 3.
Its magnitude, compared with placebo, was similar to
that after blinded active. There was no further signiﬁ-
cant change in the second year after blinded active or
open active. Moreover, there was no evidence of deteri-
oration in the third year after blinded active.
Mean torque required to extend the forearm was
greater (by 239 Nm · 10
)3⁄year, i.e. 52% of baseline)
following successful blinded active than following
placebo (Table 3), irrespective of anti-parkinsonian
medication. Successful open active had a statistically
signiﬁcant effect on torque to extend, approaching the
same magnitude relative to placebo (Fig. 3). There was
no signiﬁcant time-trend in the second year after an
active treatment. A small deterioration in the third year
after blinded active was insufﬁcient to affect stride.
Torque to ﬂex the forearm had a lower baseline than that
to extend (Table 2): the characteristic parkinsonian
rigidity pattern. It was unaffected by treatment (Table 3).
Thus, two facets of parkinsonism dissociate after erad-
icating Helicobacter, with change in stride and rigidity in
mirror image (Fig. 3).
Tremor during stance⁄walk tended to increase after
placebo relative to blinded active, the size of effect
being large ()26⁄year in the 10 probands with tremor
ratings ‡90⁄100, where 100 is no tremor, 0 most intru-
sive). Increase in torque to extend after blinded active
may have dampened tremor. Tremor while seated was
not sensitive to the treatment-effect. Anxiety at the
hands being under scrutiny may have dominated.
Successful Helicobacter eradication had no effect on
postural measures, cognitive efﬁciency, mean arterial
pressure and pulse, or body weight.
Failed Eradication
Table 4 gives the detailed analysis of time-trends in
four probands with evidence of failed eradication,
compared with the ﬁrst year after successful treatment
in the remaining 26. All failures were receiving back-
ground anti-parkinsonian medicine. Their cytotoxic
T-cell (CD8+) count was lower by 323 (95% CI 50,
596)⁄lL (adjusted for age and gender [3], p = .02).
(Median 526 (interquartile range 390, 641)⁄lLi n
remainder, corrected to mean age 60 year and as if all
subjects male). Total white cell, neutrophil, lymphocyte,
T helper (CD4+), B cell (CD19+) and natural killer
(CD16+56+) counts did not differ. All failures, but only 6
of the remainder, were ANA positive (Fisher’s exact
test, p = .008).
Stride length was worse by, on average, 210 mm⁄
year with eradication failure compared with the
remainder, with a concomitant relative decline in
free-walking speed (169 mm⁄second⁄year). Subjective
assessment of videos was able to detect a difference of
this magnitude ()14⁄year, where 100 is normal, 0
severe brady⁄hypokinesia).
Torque to extend the forearm was numerically
greater with eradication failure, but the difference from
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Torque to ﬂex was unaffected.
Tremor, body sway, and standing height were
unaffected, but foot separation tended to be nar-
rower (21 mm) with failure. It had no effect on
cognitive efﬁciency or blood pressure. With failure,
pulse rate was lower by 12⁄minute⁄year lying and
by 10 standing, the effect being masked by exer-
cise. Weight loss with failure was clinically
unimportant.
Table 2 Pre-randomization characteristics of efﬁcacy-study subjects
Characteristics
Mean (data interval)
Placebo (n = 16) Active (n = 14)
Demographic⁄anthropometric
Age (years) 63 (45, 81) 59 (41, 78)
Gender
a 13 M, 3 F 6 M, 8 F
Height (m) 1.72 (1.57, 1.88) 1.69 (1.48, 1.89)
Weight (kg) 80.9 (53.8, 108.2) 77.9 (50.5, 105.2)
Mini-mental score (maximum 30)
b 28 (27, 29.5) 29 (29, 30)
Modiﬁed Tooting Bec score (16)
b 15.25 (15, 16) 15.75 (15, 16)
Beck’s Hopelessness score (20)
b 3 (1, 5) 3.5 (2, 6)
Background anti-parkinsonian medication (no⁄yes) 8⁄89 ⁄5
Brady⁄hypokinesia
Mean stride length (mm) 1244 (909, 1579) 1222 (806, 1638)
Free-walking speed (m⁄second) 1.20 (0.79, 1.60) 1.14 (0.64, 1.65)
Rigidity
Mean torque to extend forearm (Nm · 10
)3)
c 400 (156, 1026) 463 (160, 1335)
Mean torque to ﬂex (Nm · 10
)3)
c 290 (111, 756) 326 (165, 643)
Tremor rating (100 none, 0 worst) global scale
Mean tremor seated rest
b 96.7 (83.4, 100) 92.2 (69.5, 97.5)
Mean tremor seated, stress
b 88.8 (74.3, 100) 88.0 (62.0, 98.5)
Mean tremor during stance⁄walk
b 92.3 (89.3, 100) 95.4 (96.9, 100)
Postural abnormality
Mean body sway, eyes open
 C 5.6 (2.2, 14.4) 5.1 (2.2, 11.5)
Mean body sway, eyes closed
 C 9.1 (3.1, 27.1) 8.2 (2.8, 24.1)
Mean foot separation (mm) 198 (149, 247) 194 (144, 244)
Psychomotor and psychometric measures
Mean unwarned reaction time (ms)
c 608 (408, 907) 566 (369, 868)
Mean warned reaction time (ms)
c 366 (206, 653) 347 (197, 611)
Histopathology and microbiology, gastric biopsies
a
Helicobacter-like organisms on histology
d 15 14
Culture +ve 16 13
e
Metronidazole resistance, antral biopsy
f 6 (1) 5 (2)
Metronidazole resistance, corporal
f 6 (1) 3 (2)
Immunoblot +ve for CagA antibody 13 13
Inspection shows no evidence of a pre-randomization characteristic (except gender) being associated, by chance, with a randomization category.
In the analysis, outcome measures are corrected for personal characteristics (including gender), where pre-determined to be appropriate.
aCount.
bMedian (interquartile range).
cExponential of loge transformation (see Statistical Methods).
dPangastritis (n = 12), antral predominant (17), corpus predominant (1). Chronic inﬂammatory activity (grading normal as 0, mild 1, moderate 2,
marked 3) not signiﬁcantly different for active and placebo randomizations in antrum (median (interquartile range) 2(2, 2), 2(1, 2), respectively) or
corpus 1(0, 2), 1(1, 1), nor was polymorphonuclear activity (antrum: 1(1, 1), 1(1, 2); corpus: 1(0, 1), 1(0, 1)) or Helicobacter pylori density (antrum:
2(2, 2), 2(2, 3); corpus: 1(1, 2), 1(1, 2)). Atrophy (n = 5 (marked in 1, moderate 2, mild 2); intestinal metaplasia in 4 of these (marked 2, mild 2)) not
associated with randomisation category.
eIn remaining subject, PCR for H. pylori (vacA) positive on both biopsies, clarithromycin mutation assay showing wild (sensitive) type.
fNumber with metronidazole resistance (intermediate susceptibility). All cultures sensitive to clarithromycin, amoxicillin, and tetracycline.
Second-line anti-microbial regimen prescribed in four subjects (blinded active randomization) because of history of intolerance: Rx clarithyromycin
with metronidazole in three, with tetracycline in one.
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Modiﬁer in ‘‘Successful’’ Eradication
Excluding known eradication failures, stride length
declined in the ANA positive compared with the ANA
negative, by, on average, 173 mm in the ﬁrst year
after anti-Helicobacter therapy (Table 4). There was a
concomitant relative decline in free-walking speed
(149 mm⁄second⁄year). The effect was not con-
founded by background anti-parkinsonian medication
(Fig. 4).
Torque to extend the forearm was less by
304 Nm · 10
)3⁄year in the ANA positive (Table 4), irre-
spective of anti-parkinsonian medication, as though
positivity ‘‘protects’’ against the increase in rigidity
expected with successful eradication. Torque to ﬂex also
showed a numerically greater decline (156 Nm ·
10
)3⁄year) in the ANA positive, but the difference
reached signiﬁcance only at the .1 level.
Tremor during stance⁄walk worsened in the ANA
positive (47⁄year in those with tremor ratings ‡90⁄100)
relative to the ANA negative, consistent with relative
Table 3 Effect of blinded- and open-Helicobacter eradication on within-subject time-trends in outcome criteria for idiopathic parkinsonism
Outcome variable
Estimated change in blinded phase
ab
Mean (95% CI)⁄year
p-value
Estimated change subsequent year
a
Mean (95% CI)⁄year
p-value
Placebo
86 assessments
(n = 16)
Active
82 assessments
(n = 12)
c
Open active
81 assessments
(n = 14)
c
Post-blinded active
30 assessments
(n = 12)
Brady⁄hypokinesia
d
Stride length (mm) 3 ()47, 52) 75 (41, 110) .01 69 (2, 136) )26 ()121, 70) .08
Free-walking speed (mm⁄second) 86 (1, 174) 92 (30, 153) .9 83 (2, 163) )27 ()148, 94) .1
Rigidity (Nm · 10
)3)
Torque to extend )1( )141, 143) 238 (115, 361) .01 197 (49, 344) 92 ()94, 278) .4
Torque to ﬂex 1 ()92, 94) 59 ()214, 140) .3 47 ()105, 200) )23 ()141, 95) .4
Tremor rating (100 none, 0 worst)
global scale
Tremor seated
e )3( )11, 4) 0 ()5, 6) .4 )11 ()19, )2) )1( )13, 11) .2
Tremor stance⁄walk )5( )12, 3) 4 ()2, 9) .07
f 0( )9, 8) )13 ()26, 1) .1
Postural abnormality (%)
g
Body sway )2( )8, 4) 3 ()2, 8) .2 )1( )7, 5) )2( )12, 8) .8
Ratio sway: eyes open⁄closed 2 ()6, 10) 2 ()5, 9) .9 5 ()4, 14) )3( )16, 11) .3
aMedian follow-up before deblinding: 263 (inter-quartile range 103–378) days following placebo (n = 16, with premature deblinding in 9), and 352
(261–370) following successful blinded active treatment (n = 12, with premature deblinding in 3). There was evidence of eradication failure in two
probands receiving blinded active, and two receiving open active.
bFollowing unaffected in protocol analysis: psychometric function, mean arterial pressure, pulse and body weight.
cParameter estimates were similar, when failure of eradication was used as an effect-modiﬁer in whole group, to estimates where failures were
simply excluded.
dNo signiﬁcant effect of eradication therapy on subjective brady⁄hypokinesia video rating.
eNo signiﬁcant effect of eradication therapy on increment in tremor under stress.
fAfter excluding those with tremor ratings of ‡90⁄100 on stance⁄walk, size effect: )18 (95% CI )42, 7)⁄year after placebo (n = 6, 29 observations),
8( )7, 24) after blinded active (n = 4, 29 observations), p = .06.
gNo signiﬁcant effect of eradication therapy on ambulatory foot separation.
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Figure 2 Comparison of time-trend in stride length, following double-
blind successful-active Helicobacter pylori eradication therapy and
placebo, between entire group (n = 28) and those not exposed to
background anti-parkinsonian (IP) medication (n = 17). Estimated
change (95% CI) over a year is shown. After excluding those on
anti-parkinsonian medication, difference between treatments remained
signiﬁcant (p = .035), size of effect similar (placebo: 5 ()45, 55)
mm⁄year (n = 8); active: 72 (35, 109) (n = 9)). Two probands, in whom
blinded active treatment failed, are excluded: they and 11 others were
receiving background medication.
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while seated was unaffected.
Provocation of imbalance by closing the eyes was
greater (17%⁄year) in the ANA positive, but standing
sway overall, height and ambulatory foot separation
were unaffected. ANA status had no effect on cognitive
efﬁciency, mean arterial pressure, pulse or body weight.
Anti-nuclear antibody status was not associated with
the presence⁄absence of antibody against cytotoxicity-
associated gene product (CagA) on the immunoblot.
This was addressed because anti-CagA-seropositivity is
associated with greater deterioration in parkinsonian
facets with time [36].
Eradication of Low-Density H. pylori Infection:
Case History
Acid regurgitation and bloating with nausea resolved
following Helicobacter eradication (possibly due to
improved gastric emptying [37]), hot-sweats
disappeared.
There was marked sustained improvement in stride
length and free-walking speed from the ﬁrst assessment
following eradication, at 6 weeks, until the last assess-
ment 3.4 years after (Fig. 5). Stride length improved by
424 (95% CI 379–468) mm for 15 months post-eradica-
tion (p = .001), and correction of the deﬁcit continued.
She remained free from anti-parkinsonian medication
throughout.
Following the baseline (phase 1), serial hydrogen-
breath-tests remained negative (3⁄3) over 450 days
post-eradication (phase 2). They were positive (6⁄7)
over the next 500 days (phase 3). Over the 300 subse-
quent days (phase 4), when bulk and osmotic laxatives
were exhibited and ﬂuid consumption increased, tests
were negative (3⁄3). The interposing period of hydro-
gen-breath-test positivity did not inﬂuence stride length
or free-walking speed. Subjective assessment of videos
easily detected the improvement of brady⁄hypokinesia,
in phases 2, 3, and 4. Over baseline (p = .001, in each
case).
Figure 6 (lower) shows that torque to extend the
forearm was greater in phases 2–4 than at baseline. It
was greater during the period of hydrogen-breath-test
positivity (phase 3) than in preceding and succeeding
periods of negativity. Torque to ﬂex was lower than
that to extend, and relatively unchanged throughout.
There was a small (average 1 cm), but signiﬁcant, loss
Figure 3 Schematic representation of effect of eradicating
Helicobacter, on hypokinesia and rigidity, over 2 years. Estimated
mean time-trends in stride length and torque to extend forearm
following successful blinded active (red, n = 12) and placebo (blue,
n = 16) are shown. Change in outcome measure is also given for year
2 after blinded active (red, n = 12), and for each of the 2 years follow-
ing successful open active (orange, n = 14). Time-trends for the year
after blinded active or open active were signiﬁcant (stride length:
p = .001 and .04, respectively; torque: p = .001 and .009). Time-trends
after placebo and in year 2 after blinded active were not (Table 3),
neither were those in the second year after open active (n = 8 with 48
assessments). There was no signiﬁcant time-trend in stride length
(n = 9 with 40 assessments) in year 3 after blinded active (or even on
pooling year 2 and 3 data). However, a signiﬁcant increment in torque
(88 (95% CI 15, 161) Nm · 10
)3, p = .02) occurred in year 3.
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Figure 4 Comparison of time-trend in stride length, in anti-nuclear
antibody (ANA) positive and negative, between the entire group with
‘‘successful’’ Helicobacter pylori eradication (n = 26) and those not
exposed to background anti-parkinsonian (IP) medication (n = 17).
Estimated change (95% CI) over a year is shown. After excluding those
on anti-parkinsonian medication, difference with ANA status remained
signiﬁcant (p = .02), size of effect similar (ANA positive: )60 ()162, 43)
mm⁄year (n = 4); ANA negative: 65 (34, 96) (n = 13)). Four probands
in whom active treatment failed are excluded: they and six of the
remainder were ANA positive.
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compatible with a more ﬂexed posture. Increase in
torque to extend was accompanied by reduction in tre-
mor, decrease by worsening of tremor (Fig. 6, upper).
Body sway decreased following Helicobacter eradica-
tion, and dependence of balance on vision was consis-
tently less (Table 5). There was a concomitant increase
in ambulatory foot separation. Sustaining a walk over
18 m had been difﬁcult at baseline. Improvement in
balance was also evidenced by the patient cycling
10 miles. Although there was a statistically signiﬁcant
fall in mean arterial pressure, supine (by 8 mmHg)
and post-exercise (13 mmHg), the latter evidently did
not affect balance adversely (Table 5). Her 5.2 kg
weight loss should reduce sway, have no effect on
reliance on vision and make foot separation narrower.
(Weight is a covariate for sway and foot separation
[7]). Weight loss may be due, in part, to decreased
stasis edema.
There was no change in cognitive efﬁciency between
phases. However, mean reaction time was signiﬁcantly
(p = .02) faster during hydrogen-breath-test positivity
(phase 3) than at baseline (572 (95% CI 496, 659), 529
(497, 562), 477 (467, 509) and 493 (449, 543) ms for
phases 1–4, respectively).
Discussion
Towards a Paradigm Shift
We question the classiﬁcation of IP as non-communica-
ble, and the corollary that any constitutional illness in
probands has a separate cause. A whole template for
ameliorating or halting progression is set aside by
Table 4 Natural experiment of eradication failure, and effect of anti-nuclear antibody (ANA) status, on within-subject time-trends in outcome
criteria for idiopathic parkinsonism, in ﬁrst year post-active treatment
Outcome variable
Estimated change⁄year
ab
Mean (95% CI)
p-value
Estimated change⁄year
ab
Mean (95% CI)
p-value
Evidence failed
eradication
c
22 assessments
(n = 4)
Remainder
153 assessments
(n = 26)
Remainder
ANA +ve
25 assessments
(n = 6)
Remainder
ANA )ve
128 assessments
(n = 20)
Brady⁄hypokinesia
d
Mean stride length (mm) )158 ()273, )43) 52 (17, 87) .001 )105 ()196, )14) 68 (33, 102) .001
Mean free-walking speed (mm⁄second) )97 ()271, 76) 72 (19, 124) .046 )64 ()206, 79) 85 (31, 139) .045
Rigidity (Nm · 10
)3)
Mean torque to extend 374 (76, 672) 160 (61, 258) .1 )113 ()346, 121) 191 (92, 291) .01
Mean torque to ﬂex )41 ()283, 201) )2( )83, 80) .7 )140 ()333, 53) 16 ()68, 101) .1
Tremor
Mean tremor seated (mm)
e )8( )24, 8) )3( )8, 2) .7 5 ()8, 18) )4( )8, 2) .2
Mean tremor stance⁄walk (%) 4 ()11, 19) 2 ()3, 7) .7 )15 ()26, )3) 4 ()1, 8) .003
f
Postural abnormality (%)
g
Mean body sway 0 ()42, 78) 5 ()12, 24) .9 )9( )46, 44) 6 ()11, 26) .5
Ratio mean sway: eyes open⁄closed )12 ()28, 8) )1( )7, 6) .2 )16 ()29, 0) 1 ()5, 8) .04
aMedian follow-up after known eradication failure was 268 (range 78–416) days, and, in remainder 544 (inter-quartile range 245, 1059).
bPsychometric function was unaffected by either eradication failure or ANA status. Mean arterial pressure was unaffected, but pulse lower with
eradication failure ()11 (95% CI )20, )1) vs 1 (0, 3) supine; )9( )19, 1) vs 1 (0, 3)⁄minute⁄year standing over 3 minutes: p = .01 and .048
respectively). Weight loss was greater with failure ()0.3 ()1.3, 0.1) vs 0.6 ()0.2, 1.4) kg, p = .03). ANA status had no signiﬁcant effect on these
outcomes in remainder.
cCriterion: UBT (n = 1), histology and culture (1), molecular detection only (2). UBT available in all 30 following an active treatment, 26⁄30 having a
repeat endoscopy at a median of 346 (inter-quartile range 31, 387) days. Classiﬁcation and grading of gastritis improved (even in those with
evidence of eradication failure) or returned to normal, in all but one. The exception had a minor degree of chronic antral gastritis, with
Helicobacter-like organisms before eradication, without organisms after.
dSubjective brady⁄hypokinesia video rating deteriorated with eradication failure ()13 (95% CI )25, )0.3) vs 1 ()3, 5), p = .02). It was unaffected by
ANA status in remainder.
eTremor under stress unaffected by eradication failure or ANA status.
fAfter excluding those with tremor ratings of ‡90⁄100 on stance⁄walk, size effect: )40 ()74, )6) for ANA positive (n = 2 with eight observations),
7( )5, 20) for ANA negative (n = 7 with 48 observations), p = .004.
gAmbulatory foot separation tended to be narrower with eradication failure ()28 ()51, )4) vs )7( )14, 0.5) mm, p = .07), ANA status having no
signiﬁcant effect in remainder.
Dobbs et al. Helicobacter as an Arbiter of PD Progression
ª 2010 Blackwell Publishing Ltd, Helicobacter 15: 279–294 289ignoring IP’s systemic nature [2,3], which includes
morphological⁄neurochemical changes in the enteric
nervous system [38,39], and prodromal slow gastroin-
testinal-transit [40,41] and peptic ulceration [4]. More-
over, Lewy bodies (a classical hallmark of Parkinson’s
disease) and peripheral inﬂammatory cells have been
reported in dopamine-cell brain implants [42]. The sim-
plest explanation is that the recipient’s ongoing inﬂam-
matory process affects the transplant. A more
fundamental nosological grouping could position IP at
an interface of disciplines with potential for interven-
tion in the pathogenesis. However, prevailing paradigm
bias is imposing lines of demarcation which are time
and criticism dependent [43].
Presentation and evolution of IP is diverse. Clini-
cians strive to split-off homogenous subsets, presum-
ably to reveal that necessary and sufﬁcient cause. We
reject this approach, taking a broad clinical deﬁnition
and quantifying individual facets and associated dis-
ability. Objective quantiﬁcation is optimal. It allowed a
reliable answer to the main research question: ‘‘Does
eradicating H. pylori have an effect on the primary
outcome, hypokinesia of gait?’’ It also enabled explo-
ration of factors that modify outcome, by interaction
or (like ANA status) directly. Greater understanding
of the evolution has come from unpicking how dif-
ferent facets respond to the same stimulus. Lumping
facets of the syndrome together in a ‘‘global’’ subjec-
tive score is valid only if they progress in parallel
within-proband, in set proportion between. Biological
plausibility of the work lies in a large number of
observational studies [2] ﬁtting with the current inter-
ventional one.
We show that Helicobacter infection can act as a
switch in the pathogenic circuitry: marked deterioration
in gait accompanied eradication failure, while improve-
ment accompanied success. Taken together, natural and
planned experiments incriminate Helicobacter speciﬁ-
cally. However, a subordinate pathogenic pathway,
manifest by increased ﬂexor rigidity, opened up follow-
ing successful eradication. This reproduction of the
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Figure 6 Mean (95% CI) rigidity and tremor before (phase 1) and after
(phase 2) biopsy-proven eradication of ‘‘low-density’’ Helicobacter
pylori infection, and before (phase 2), during (phase 3) and after
(phase 4) hydrogen-breath-test positivity, in case history.
Lower graph: Torque to extend forearm was less in phase 1 than sub-
sequent phases (p = .02, .001, .01, respectively), but greater in phase
3 than either phase 2 or phase 4 (p = .001 and .04). Torque to ﬂex
was less than that to extend throughout. It changed little between
phases (less in phase 2 than previously (p = .01), with a subsequent
slow return toward baseline).
Upper graph: Tremor whilst seated and during stance⁄walk showed
similar patterns. Whilst seated, it was less intrusive in phases 2 and 3
than at baseline (p = .03 and .003), but deteriorated in phase 4
compared with phase 3 (p = .001). Stance⁄walking tremor was better
than at baseline in all subsequent phases (p = .001, in each case), but
did tend to deteriorate in phase 4 compared with phase 3 (p = .08).
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ity-predominance, together with Helicobacter’s ubiquity,
suggests it is the natural arbiter for progression.
Small intestinal bacterial overgrowth is a candidate
driver for the subordinate route. It is common in IP in
the absence of Helicobacter [3]. In the case history,
ﬂexor rigidity increased on acquiring hydrogen-breath-
test positivity, decreased on regaining negativity. How-
ever, the increase pre-dated breath-test positivity, and
rigidity did not quite return to baseline after negativity
was regained. The effect may be load-related, with
pathogenic colonization without hydrogen-breath-test
positivity. Overgrowth is unlikely to be a bystander in
IP: signiﬁcant numbers of secondary lysosomes are seen
in enterocytes, when overgrowth is veriﬁed on jejunal
aspirate culture [I.T. Bjarnason, R.J. Dobbs, S.M. Dobbs,
B. Hudspith, J. O’Donohue, J.D. Sanderson, unpub-
lished observation). Other chronic infections (e.g.
urinary and periodontal disease) may be equally
harmful to an individual.
Possible Driving Mechanisms: Autoimmunity and
Load-Related’
A speciﬁc basal ganglia syndrome, Sydenham’s chorea,
has long been associated with spatially remote bacte-
rial (Group A Streptococcus) infection. The exceptional-
ity of autoimmune gastritis with Helicobacter infection
in IP [37] does not exclude cross-reactivity with
remote antigens. Autoimmunity may also best explain:
(1) beneﬁt of eradicating low-density Helicobacter infec-
tion (case history); (2) adverse consequence of its per-
sistence in low-density post-treatment (2⁄4 eradication
failures); (3) predictiveness of the immunoblot anti-
body proﬁle for risk, severity and deterioration of IP,
irrespective of anti-urease ELISA-seropositivity [36].
Removal of an autoimmune driver would be expected
to result in rapid improvement (case history). Any sec-
ondary biomechanical abnormality (e.g. ‘‘ﬁxed’’ knee
ﬂexion) may temper the speed of recovery (efﬁcacy
study). ANA marked proven failure of eradication. In
apparent success, ANA’s association with a brady⁄
hypokinetic response could indicate persistent infec-
tion, not detected by the trial methodology. In newly
recruited IP probands, in the UK, immunoblot seroposi-
tivity (50%, with further 8% equivocal) is currently
much more frequent than UBT (30%) or ELISA
(35%) positivity [3]. Immunoblot positivity was associ-
ated with a relatively higher total lymphocyte count
(by, on average 12%). Even an equivocal blot score
tended to be (16%). This suggests ongoing infection
not just memory. Propensity to low-density infection
might be greater where bacterial urease continues to
produce ammonia in the face of inhibition of acid
secretion by circulating cytokines [44]. Such auto-
inhibition could explain low-density gastric infection
without atrophy in IP. Ready access to the adaptive
immune system might be facilitated by Helicobacter
gaining access to gastric lymph nodes [45]. Although
there is little evidence to support persistence of
H. pylori in low density in dyspeptic cohorts, the blood
proﬁle of IP probands is distinctive, with relative
lymphopenia overall, a leftward shift in B-cells and a
rightward in natural killer count, compared with con-
trols [3]. Moreover, a low cytotoxic T-cell count
appears to ﬂag the risk of eradication failure. Greater
incidental anti-microbial usage in IP, if in the context
of impaired bacterial clearance, could increase the
prevalence of low-density infection.
A likely explanation of non-organism-speciﬁc,
dose-related, brain damage is activation of microglia to
produce inﬂammatory mediators and neurotoxins, with
corresponding suppression of neurotrophic support [9].
With elimination of peripheral infection, activation
would be lost, supportive function restored. Systemic
inﬂammation can evade or compromise the blood-
brain-barrier to inﬂuence the brain’s immune system
[2]. Indeed, there are biological gradients between
circulating inﬂammatory markers (cortisol, tumor
necrosis factor-a) and objective measures of parkinson-
ism (gait, sway, psychomotor response) [44,46].
A Unifying Mitochondrial Hypothesis
Mitochondrial dysfunction is described in IP, both in
the substantia nigra and peripherally [2]. In a system-
atic review [2], we propose that cross-reactivity
between Helicobacter and mitochondria underlies
brady⁄hypokinesia-predominant IP (Stage 1), and that
subsequent acquisition of SIBO stresses mitochondria
further, producing a rigidity-predominant picture (Stage
2). On electron microscopy, double-membrane-encap-
sulated arrays, not associated with rough endoplasmic
reticulum, appear to typify duodenal enterocytes of pro-
bands with Helicobacter infection [47]. They persist, in
declining density, for a year or more after successful
eradication. Long thin, sometimes complex-branching,
mitochondria predominate in probands with SIBO.
Hypertrophy, associated with rough endoplasmic reticu-
lum, may compensate for hypofunction. Involvement
of proteins made in mitochondria, which regulate mito-
chondrial function or protect against mitochondrial
poisons, are described in different genetic forms of
parkinsonism [48–50]. In sporadic IP, an environmental
factor, Helicobacter, may inﬂuence mitochondrial
morphology and dynamics. In the overlap disease of
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phology, distribution, and function appear to inﬂuence
synaptic function [51].
Attempt to Accommodate Helicobacter Without
Paradigm Shift
Speculation about the adverse effect of Helicobacter gas-
tritis on totality of levodopa absorption [52] evades a
radical move away from the consensus view. The puta-
tive mechanism is decreased acid secretion, through
inhibition by cytokines or because of atrophic gastritis.
However, atrophy more than minimal⁄mild was unu-
sual in the efﬁcacy study. Perhaps more importantly for
absorption, the delayed gastric emptying of IP can
improve following Helicobacter eradication [37]: this
might impact on predictability of response to such a
short t½ medication.
Levodopa absorption is irrelevant in this study: no
proband received it. Moreover, improvement was
irrespective of any background anti-parkinsonian
medication.
Summary of Clinical and Research Implications
of Work
The size of effect of eradicating H. pylori on gait (efﬁcacy
study) was clinically relevant (i.e. similar to that of giv-
ing levodopa, after overnight deprivation, in probands
experiencing end-of-dose effect [18]). It was maintained
for at least 2 years, acquisition of increased ﬂexor tone
being insufﬁcient to annul improvement. Eradication
corrected the marked gait deﬁcit in the case history.
There is good reason to rank tremor, where present, as a
subsidiary outcome to rigidity: tremor decreased with
increase in ﬂexor tone, and vice versa. Acquisition of
SIBO appeared to dampen the intrusive tremor (case
history), regaining hydrogen-breath-test negativity to
allow its re-emergence. Balance is critical to realizing
functional potential. All three relevant measures (body
sway, its dependency on vision, ambulatory breadth-of-
base) improved in unison with Helicobacter eradication
(case history). Individual measures worsened with
known or presumed eradication failure (efﬁcacy study):
breadth-of-base tended to narrow with known eradica-
tion failure, visual dependency increased in the ANA
positive. Supine mean arterial pressure fell progressively
following Helicobacter eradication [53], with a corre-
sponding rise in pulse rate (case history): obesity and
ﬂuid retention, associated with elevated serum cortisol
[46], may have contributed to initial pressures. Pulse fell
with known failure. Cognitive efﬁciency was unaffected
by treating Helicobacter.
It is easy to translate work superﬁcially, to the detri-
ment of patients: hence the need to establish robust epi-
demiological data and guidelines now. Experience so far
suggests that a noninvasive test-and-treat policy for Heli-
cobacter in IP is inadvisable, due to the dramatic deterio-
ration in parkinsonism which can follow failure. We
recommend endoscopic biopsy, to obtain anti-microbial
sensitivities at presentation, and in conﬁrming Helicobact-
er eradication, with PCR assay in the culture negative.
Any effect of Helicobacter eradication on acquisition of
SIBO needs to be deﬁned, as do those of acquiring and
eliminating SIBO on rigidity. Common sense life-style
changes, involving adequate ﬂuid and ﬁber intake, and
Table 5 Balance before (phase 1) and after (2) Helicobacter eradication, and before (2), during (3) and after (4) hydrogen-breath-test positivity, in
case history
Characteristic
a
Mean (95% CI)
Phase 1 Phase 2 Phase 3 Phase 4
Mean body sway 
b 14 (11, 17), 9 (8, 10) 9 (8, 11) 7 (6, 9)
Mean ratio sway: eyes open⁄closed (%)
c 27 (21, 36) 74 (66, 84) 67 (59, 76) 51 (41, 64)
Mean foot separation (mm)
c 168 (160, 175) 195 (191, 200) 193 (188, 197) 192 (186, 199)
aSupine mean arterial pressure numerically lower in successive phases, difference from baseline signiﬁcant (p = .046) at phase 4 (mean 102 (95%
CI 95, 108) and 94 (90, 98) mmHg for phases 1 and 4, respectively). Similar trend in standing pressure did not reach statistical signiﬁcance, but
progressive fall in post-exercise pressure did (112 (105, 119) and 99 (94, 104) for phases 1 and 4, p = .003). Supine pulse increased signiﬁcantly
(p = .009) over baseline by phase 4 (69 (64, 74) and 78 (74, 81)⁄minute for phases 1 and 4), standing tended to, but post-exercise pulse
unchanged.
Body weight progressively decreased from baseline (81.9 (78.9, 84.9), 79.3 (76.8, 81.7), 77.3 (74.8, 79.7) and 76.7 (73.9, 79.6) kg for phases 1–4
respectively, p = .04, .005, and .007).
bFor comparison of phases 2, 3, and 4 with phase 1, p = .005, .007, and .001 respectively.
cFor comparison of phases 2, 3, and 4 with phase 1, p = .001 in each case.
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well justiﬁed to ensure patient uptake.
Old-fashioned meticulous observation in efﬁcacy
studies can unravel pathogenetic and therapeutic
effects, beyond the scope of intention-to-treat trials.
Insights from case studies, where potentially important
modifying factors have been recorded and associated
with clinical observations (e.g. SIBO with rigidity), fur-
ther our understanding of pathogenesis. Such detail is
difﬁcult to encompass in a single trial. Although ran-
domization will, on average, ensure balance between
groups in unrecorded modifying effects, the ‘‘noise’’
they introduce will add to the general variation in out-
come, making intervention appear less effective.
Clearly, the effects here need to be reproduced, taking
into account geographical differences in host and micro-
bial modifying factors. Regulation of systemic inﬂamma-
tion and immunity by host genes might prove equally
important to bacterial virulence factors [2], in determin-
ing age of presentation with IP.
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